Theravance Biopharma SVP Rhonda Farnum sells $226k in stock

Theravance Biopharma's Senior Vice President of Communications & Medical Affairs, Rhonda Farnum, sold 13,314 shares of the company's stock on September 15, 2026, for a total of $226,793. The sale was made through a pre-arranged 10b5-1 trading plan established on September 3, 2025. As of the sale, Farnum holds 213,476 shares of Theravance Biopharma.

The company's stock is currently trading at $17.04, with a market capitalization of approximately $885 million. Analysts consider the stock overvalued, placing it on the Most Overvalued list. Despite recent developments, including a proposed acquisition by Zymeworks Inc., Farnum has remained committed to her role at the biopharmaceutical company.